selected scholarly activity
-
chapters
- Haemopoietic Stem Cell Processing and Storage. 455-465. 2017
-
conferences
- 316P First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study. Annals of Oncology. S1594-S1595. 2023
- INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION. Bone Marrow Transplantation. 479-479. 2023
- NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY. Bone Marrow Transplantation. 366-367. 2023
- WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS. Bone Marrow Transplantation. 479-480. 2023
- Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. S120-S121. 2023
- Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. S24-S24. 2023
- Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG). Clinical Lymphoma, Myeloma and Leukemia. S197-S197. 2023
- Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program. Clinical Lymphoma, Myeloma and Leukemia. S147-S147. 2023
- Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database. Clinical Lymphoma, Myeloma and Leukemia. S215-S215. 2023
- Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma. Blood. 7306-7307. 2022
- Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 427-429. 2022
- Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database. Blood. 7192-7194. 2022
- Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma. Blood. 10002-10004. 2022
- International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation. Blood. 5225-5227. 2022
- Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study. Blood. 423-424. 2022
- Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood. 5223-5224. 2022
- Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 4287-4289. 2022
- Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 289-291. 2022
- Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 2395-2396. 2022
- Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers. Blood. 4839-4842. 2022
- International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation. Bone Marrow Transplantation. 44-45. 2022
- Gender disparities in multiple myeloma publications. eJHaem. 966-969. 2022
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. Journal of Global Oncology. e2200119. 2022
- OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study. Clinical Lymphoma, Myeloma and Leukemia. S25-S26. 2022
- Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomide-containing regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. S145-S146. 2022
- P-136: Global myeloma trial participation and drug access in the era of novel therapies. Clinical Lymphoma, Myeloma and Leukemia. S110-S110. 2022
- P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia. S140-S140. 2022
- P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. S145-S146. 2022
- P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Clinical Lymphoma, Myeloma and Leukemia. S180-S181. 2022
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia. S140-S140. 2022
- Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Clinical Lymphoma, Myeloma and Leukemia. S180-S181. 2022
- Gender disparities in multiple myeloma publications.. Journal of Clinical Oncology. e23000-e23000. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 12031-12031. 2022
- Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2021
- Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood. 116-116. 2021
- Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 4721-4721. 2021
- Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma. Blood. 1653-1653. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. ehab724.2876. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. 2876-2876. 2021
- Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. S162-S162. 2021
- P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. S162-S162. 2021
- Decision making factors that influence treatment options for an autologous stem cell transplant for older adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods.. Blood. 13-13. 2020
- Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. Blood. 26-27. 2020
- Is tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 18-19. 2020
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 6-7. 2020
- Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 5-7. 2020
- Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. Blood. 30-31. 2020
- Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. Blood. 1-2. 2020
- Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood. 4774-4774. 2019
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort. Blood. 268-268. 2019
- GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT. Journal of Geriatric Oncology. S73-S74. 2019
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. e232-e233. 2019
- Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 1679-1682. 2017
- The laboratory profile that predicts favorable outcome after Eculizumab therapy in patients with clinical features compatible with atypical hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis. 712-712. 2015
- Characterization of Pulmonary Compliance in Sickle Cell Patients Revealed Wide Variability. Blood. 989-989. 2013
- Attrition rates in Multiple Myeloma: A Canadian Myeloma Research Group
- Duration of Eculizumab therapy for a clinical response in atypical hemolytic uremic syndrome.
- Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma.
- Quality of life assessment in older patients with Newly Diagnosed Multiple Myeloma.
- Survival and outcomes of Newly-Diagnosed Multiple Myeloma patients stratified by transplant status diagnosed between 2007-2018: Real-World Analysis from the Canadian Myeloma Research Group
- Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study
- Trends in autologous hematopoietic stem cell transplant in older patients with Multiple Myeloma 2000-2017: The Canadian Experience
-
journal articles
- Treatment of elderly and frail myeloma patients.. Presse Medicale. 104266. 2024
- Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.. Blood Advances. 8:5993-6002. 2024
- Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC: CardioOncology. 6:815-834. 2024
- Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit.. Clinical Lymphoma, Myeloma and Leukemia. S2152-2650(24)02420-0. 2024
- A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 144:1985. 2024
- A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144:2000.2-2000.2. 2024
- Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144:1994. 2024
- Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee. Blood. 144:5166-5166. 2024
- Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody. Blood. 144:4757.1. 2024
- Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis. Blood. 144:704. 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144:3355-3355. 2024
- Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium. Blood. 144:3368-3368. 2024
- Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 144:5170.3-5170.3. 2024
- Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 144:703. 2024
- ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma. Blood. 144:6916-6916. 2024
- Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis. Blood. 144:6986. 2024
- Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.. Cancer Medicine. 13:e70332. 2024
- Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).. American Journal of Hematology. 99:2084-2095. 2024
- Quadruplets in newly diagnosed transplant-ineligible multiple myeloma.. American Journal of Hematology. 99:2249-2252. 2024
- Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.. Leukemia and Lymphoma. ahead-of-print:1-14. 2024
- First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium.. Clinical Lymphoma, Myeloma and Leukemia. S2152-2650(24)02385-1. 2024
- Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.. Blood Cancer Journal. 14:181. 2024
- Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement.. Leukemia and Lymphoma. ahead-of-print:1-10. 2024
- Still high risk? A review of translocation t(14;16) in multiple myeloma. American Journal of Hematology. 99:1979-1987. 2024
- Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.. Blood Cancer Journal. 14:155. 2024
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.. Oncologist. oyae219. 2024
- P-161 Gut Microbiota Differences Among Transplant Ineligible Patients With Newly-Diagnosed Multiple Myeloma Treated With dara-len-dex. Clinical Lymphoma, Myeloma and Leukemia. 24:s131-s132. 2024
- P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 24:s217-s218. 2024
- P-354 Real-World Comparison of Progression Free Survival and Time to Next Therapy Endpoints in Newly Diagnosed Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 24:s237-s238. 2024
- Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.. Haematologica. 2024
- Patient-Reported Outcome Measures in Cancer Care. JAMA network open. 7:e2424793-e2424793. 2024
- Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leukemia and Lymphoma. 65:1167-1174. 2024
- Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e861-e869. 2024
- Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. Transplantation and Cellular Therapy. 30:889-901. 2024
- A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma. Oncologist. 29:519-526. 2024
- Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database. eJHaem. 5:474-484. 2024
- Perspectives on geriatric oncology research presented at the 2023 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology report. Journal of Geriatric Oncology. 15:101762-101762. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e227-e234. 2024
- A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15:101735-101735. 2024
- Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature Medicine. 30:543-551. 2024
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer Journal. 14:20. 2024
- Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?. Blood Cancer Journal. 14:7. 2024
- Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer Journal. 13:181. 2023
- Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 108:3384-3391. 2023
- MRD negativity: considerations for older adults with multiple myeloma. Blood Cancer Journal. 13:166. 2023
- Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:541-541. 2023
- Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada. Blood. 142:1954-1954. 2023
- Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial. Blood. 142:4751-4751. 2023
- Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review. Blood. 142:3363-3363. 2023
- Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study. Blood. 142:785-785. 2023
- Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial. Blood. 142:4756-4756. 2023
- Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients. Blood. 142:542-542. 2023
- Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 142:3364-3364. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology. 111:815-823. 2023
- Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. Journal of Geriatric Oncology. 14:101592-101592. 2023
- Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectrum. 7:pkad100. 2023
- Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer Journal. 13:137. 2023
- A pilot study of adherence to lenalidomide among older patients with multiple myeloma. Journal of Geriatric Oncology. 14:101560-101560. 2023
- OA-39 Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 23:S24-S24. 2023
- P-155 Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 23:S120-S121. 2023
- P-203 Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program. Clinical Lymphoma, Myeloma and Leukemia. 23:S147-S147. 2023
- P-291 Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG). Clinical Lymphoma, Myeloma and Leukemia. 23:S197-S197. 2023
- P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database. Clinical Lymphoma, Myeloma and Leukemia. 23:S215-S215. 2023
- Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 13:129. 2023
- Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies. JACC: CardioOncology. 5:415-430. 2023
- Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study. American Journal of Hematology. 98:E197-E199. 2023
- Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 13:111. 2023
- Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma. Cancer. 129:2179-2191. 2023
- Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances. 7:2746-2757. 2023
- Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer. Journal of Geriatric Oncology. 14:101520-101520. 2023
- Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer Journal. 13:76. 2023
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58:478-490. 2023
- First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia. 23:340-354. 2023
- Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6. Supportive Care in Cancer. 31:256. 2023
- Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. Cancer Medicine. 12:4357-4362. 2023
- Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood Cancer Journal. 12:168. 2022
-
Quality of
end‐of‐life care in multiple myeloma: A13‐year analysis of a population‐based cohort in Ontario, Canada. British Journal of Haematology. 199:688-695. 2022 - Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 387:1721-1723. 2022
- Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.. New England Journal of Medicine. 387:1722-1723. 2022
- Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. eJHaem. 3:1252-1261. 2022
- What do hematology residents know about caring for older adults with cancer? A national survey of Canadian hematology residents' knowledge and interests. Journal of Geriatric Oncology. 13:1236-1240. 2022
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. 22:608-617. 2022
- Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances. 6:3991-3995. 2022
- Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. British Journal of Haematology. 198:93-102. 2022
- Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal. 12:74. 2022
- Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department?. Canadian Journal of Emergency Medicine. 24:256-258. 2022
- Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. Current Oncology. 29:1575-1582. 2022
- A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation. 57:295-298. 2022
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. Blood Cancer Journal. 12:17. 2022
- Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nature Reviews Clinical Oncology. 19:3-4. 2022
- Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis. Frontiers in Oncology. 12:974038. 2022
- Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. Frontiers in Oncology. 12:826342. 2022
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation. 57:31-37. 2022
- A new world of residency education: game changers and proven practices. Canadian Medical Education Journal. 12:157-246. 2021
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma, Myeloma and Leukemia. 21:e714-e721. 2021
- Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Haematologica. 106:1991-1994. 2021
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort. Leukemia. 35:1823-1827. 2021
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology. 12:508-514. 2021
- Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. Annals of Hematology. 100:1261-1266. 2021
- Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology. 12:499-507. 2021
- Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 21:e152-e159. 2021
- Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology. 11:1279-1284. 2020
- Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis. European Journal of Haematology. 105:626-634. 2020
- Caring for older patients with cancer during the COVID-19 pandemic: A Young International Society of Geriatric Oncology (SIOG) global perspective. Journal of Geriatric Oncology. 11:1175-1181. 2020
- Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncology. 6:989-989. 2020
- Simplified frailty assessment tools: are we really capturing frailty or something else?. Leukemia. 34:1967-1969. 2020
- Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology. 11:764-768. 2020
- Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. Journal of Geriatric Oncology. 11:753-760. 2020
- Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper. Journal of Geriatric Oncology. 11:735-739. 2020
- Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology. 11:203-211. 2020
- Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 20:98-104.e1. 2020
- The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?. Current Oncology. 27:10-11. 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 11:93-99. 2020
- Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia. 19:488-496.e6. 2019
- COMPARISON OF FRAILTY SCORES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: A REVIEW. Journal of Frailty and Aging. 8:1-7. 2019
- Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO clinical cancer informatics. 2:1-13. 2018
- Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging. 35:289-302. 2018
- The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Transfusion and Apheresis Science. 56:552-557. 2017
- EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis. PLoS ONE. 11:e0149830-e0149830. 2016
- Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada. Hemoglobin. 39:310-315. 2015
- Venous thrombosis in inflammatory bowel disease. CANADIAN MEDICAL ASSOCIATION JOURNAL. 187:55-55. 2015
- Crystal Structure of the Passenger Domain of the Escherichia coli Autotransporter EspP. Journal of Molecular Biology. 413:985-1000. 2011
- Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report. Journal of Pediatric Hematology/Oncology. 32:622-622. 2010
- Exploring the intersection of cancer, sepsis, and frailty: a scoping review. Discover Medicine. 1:56.
- PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM). HemaSphere. 7:e9860835-e9860835.
-
preprints